MESO Stock Analysis: Buy, Sell, or Hold?
MESO - Mesoblast Limited American Depositary Shares
$13.80
-0.13 (-0.93%)
▼
5d:
+0.0%
30d:
-8.49%
90d:
-5.67%
BUY
MODERATE Confidence
Analysis Updated: Jun 15, 2026 12:00 AM ET
Earnings: Aug 27, 2026
Get Alerted When MESO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: MESO shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: MESO shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: MESO is currently trading at $13.80, which is considered oversold relative to its 30-day fair value range of $14.14 to $15.00. From a valuation perspective, the stock is trading at a discount (Forward PE: -199.0) compared to its historical average (206.7). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, MESO is in a downtrend. The price is currently testing key support at $13.70. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: MESO has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $35.00 (+151.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, MESO is in a downtrend. The price is currently testing key support at $13.70. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: MESO has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $35.00 (+151.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$14.14 -
$15.00
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 151.3% below Wall St target ($35.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$14.14 -
$15.00
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$13.70
Resistance Level
$15.12
Current Trend
Downtrend
Technical data as of
Jun 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-199.00
Wall Street Target
$35.00
(+151.3%)
Revenue Growth (YoY)
1526.8%
Profit Margin
-144.3%
PE vs Historical
-199.0 vs 206.7
CHEAP
Share & Embed Analysis
Last updated: June 15, 2026 2:52 PM ET
Data refreshes hourly during market hours. Next update: 3:52 PM
Data refreshes hourly during market hours. Next update: 3:52 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MESO showing a specific setup today?
Insider Activity (6 Months)
4
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Gregory George
BUY
2324072 shares
2026-04-10
Gregory George
BUY
1586890 shares
2026-04-09
Gregory George
BUY
1981890 shares
2026-04-09
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 52 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 50 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$275 | 61 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$109 | 60 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$83 | 55 HOLD |
